These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26243393)

  • 21. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
    Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative helical dynamic contrast enhanced computed tomography assessment of the spatial variation in whole tumour blood volume with radiotherapy in lung cancer.
    Ng QS; Goh V; Milner J; Sundin J; Wellsted D; Saunders MI; Hoskin PJ
    Lung Cancer; 2010 Jul; 69(1):71-6. PubMed ID: 19781806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
    Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV
    Clin Lung Cancer; 2013 May; 14(3):230-7. PubMed ID: 23276821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
    Lee DH; Kim SK; Lee HY; Lee SY; Park SH; Kim HY; Kang KW; Han JY; Kim HT; Lee JS
    J Thorac Oncol; 2009 Jul; 4(7):816-21. PubMed ID: 19487962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
    J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience.
    Fraioli F; Anzidei M; Zaccagna F; Mennini ML; Serra G; Gori B; Longo F; Catalano C; Passariello R
    Radiology; 2011 May; 259(2):574-82. PubMed ID: 21357523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relationship between multi-slice spiral CT pulmonary perfusion imaging and the expression of EphB4 and ephrinB2 in non-small cell lung cancer].
    Xiong Z; Liu JK; Zhou ML; Hu CP; Zhou H; Chen W
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):192-6. PubMed ID: 21575518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
    Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Semiautomatic Analysis on Computed Tomography in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Reproducibility and Prognostic Significance of Unidimensional and 3-dimensional Measurements.
    Colombi D; Manna C; Montermini I; Seletti V; Diciotti S; Tiseo M; Fontana E; De Filippo M; Silva M; Sverzellati N
    J Thorac Imaging; 2015 Sep; 30(5):290-9. PubMed ID: 25837590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of cavitation of advanced NSCLC treated by rh-endostatin combined with NP chemotherapy].
    Huang C; Wang LC; Xiao JY; Ye ZX; Liu ZJ; Xu WJ; Cheng X; Wang J; Li K
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):712-5. PubMed ID: 19173919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of clinical outcomes of antiangiogenic-targeted therapy in patients with pulmonary metastatic renal cell carcinoma using non-contrast-enhanced computed tomography.
    Wu GY; Suo ST; Kong W; Jin D; Zhang J; Xu JR
    Acad Radiol; 2014 Nov; 21(11):1434-40. PubMed ID: 25097010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes of tumor size and tumor contrast enhancement during radiotherapy for non-small-cell lung cancer may be suggestive of treatment response.
    Okada H; Hontsu S; Miura S; Asakawa I; Tamamoto T; Katayama E; Iwasaki S; Kimura H; Kichikawa K; Hasegawa M
    J Radiat Res; 2012; 53(2):326-32. PubMed ID: 22327173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging.
    Yabuuchi H; Hatakenaka M; Takayama K; Matsuo Y; Sunami S; Kamitani T; Jinnouchi M; Sakai S; Nakanishi Y; Honda H
    Radiology; 2011 Nov; 261(2):598-604. PubMed ID: 21852569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
    Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
    Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
    Kahraman D; Holstein A; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Dietlein M; Wolf J; Kobe C
    Clin Nucl Med; 2012 Nov; 37(11):1058-64. PubMed ID: 23027207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.